Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's presentation is scheduled for Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT).

The company will engage in in-person meetings with the investment community during the conference. Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.

News Market Reaction – TBPH

-0.92%

-0.92% Session move

In the trading session that priced this news, TBPH declined 0.92%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45^th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT) and will be hosting in-person meetings with the investment community at the conference.

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302381018.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma (TBPH) presenting at the TD Cowen Healthcare Conference 2025?

Theravance Biopharma will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 am EST.

How can investors access TBPH's TD Cowen conference presentation?

Investors can access the webcast through Theravance.com, under the Investors section, Events and Presentations.

How long will TBPH's TD Cowen conference presentation be available for replay?

The webcast replay will be archived on Theravance's website for 30 days following the presentation.

What type of investor engagement is TBPH offering at the TD Cowen conference?

Theravance Biopharma will be hosting in-person meetings with the investment community during the conference.